A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
- Citation:
- Cancer Chemother Pharmacol vol 63 (5) 859-64
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA33601, CA11789, CA02599, CA47577, CA47555, CA32291, CA41287, CA03927, U10 CA033601, CA60138, CA 33601, CA77440, CA74811, CA47559, CA45418, CA77658, CA31983, CA31946
- Corr. Author:
- Authors:
- Richard M Stone Kathleen A Donohue Wendy Stock Vera Hars Charles A Linker Thomas Shea Daniel J Deangelo Guido Marcucci Clara D Bloomfield Richard A Larson
- Networks:
- Study
- CALGB-19804
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Harringtonines, Humans, Infusions, Intravenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Neoplasm Staging, Palliative Care, Prognosis, Prospective Studies, Risk Factors, Survival Rate, Time Factors, Treatment Outcome